E
Elsebeth Lynge
Researcher at University of Copenhagen
Publications - 484
Citations - 19048
Elsebeth Lynge is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Population & Breast cancer. The author has an hindex of 59, co-authored 461 publications receiving 17055 citations. Previous affiliations of Elsebeth Lynge include Statens Serum Institut & Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
The Danish National Patient Register
TL;DR: Although the NPR is overall a sound data source, both the content and the definitions of single variables have changed over time and researchers using the data should carefully consider potential fallacies in the data before drawing conclusions.
Journal ArticleDOI
Occupation and cancer – follow-up of 15 million people in five Nordic countries
Eero Pukkala,Jan Ivar Martinsen,Elsebeth Lynge,Holmfridur Gunnarsdottir,Pär Sparén,Laufey Tryggvadottir,Elisabete Weiderpass,Kristina Kjærheim +7 more
TL;DR: Mesothelioma was the cancer type showing the largest relative differences between the occupations, and plumbers, seamen and mechanics were the occupations with the highest risk in the present study.
Journal ArticleDOI
European guidelines for quality assurance in colorectal cancer screening and diagnosis : Overview and introduction to the full Supplement publication.
L. von Karsa,Julietta Patnick,Julietta Patnick,Nereo Segnan,Wendy Atkin,Stephen P Halloran,Stephen P Halloran,Iris Lansdorp-Vogelaar,N. Malila,Silvia Minozzi,Sue Moss,Philip Quirke,Robert Steele,Michael Vieth,Lars Aabakken,Lutz Altenhofen,R. Ancelle-Park,N. Antoljak,A. Anttila,Paola Armaroli,S. Arrossi,Joan Austoker,Rita Banzi,Cristina Bellisario,J. Blom,Hermann Brenner,Michael Bretthauer,M. Camargo Cancela,Guido Costamagna,Jack Cuzick,M. Dai,Jill Daniel,Jill Daniel,Evelien Dekker,N. Delicata,S. Ducarroz,H. Erfkamp,J. A. Espinàs,J. Faivre,L. Faulds Wood,Anath Flugelman,S. Frkovic-Grazio,Berta M. Geller,Livia Giordano,Grazia Grazzini,Jane Green,C. Hamashima,C. Herrmann,Paul Hewitson,Geir Hoff,Holten Iw,R. Jover,Michal F. Kaminski,E. J. Kuipers,Juozas Kurtinaitis,René Lambert,Guy Launoy,W. Lee,R. Leicester,Marcis Leja,David A. Lieberman,T Lignini,Eric Lucas,Elsebeth Lynge,S. Mádai,J. Marinho,J. Maučec Zakotnik,G. Minoli,C. Monk,António Pedro Delgado Morais,Richard Muwonge,Marion R. Nadel,L. Neamtiu,M. Peris Tuser,Michael Pignone,Christian Pox,M. Primic-Zakelj,J. Psaila,Linda Rabeneck,David F. Ransohoff,M. Rasmussen,Jaroslaw Regula,J. Ren,Gad Rennert,J. F. Rey,Robert H. Riddell,Mauro Risio,Vitor Rodrigues,H. Saito,Catherine Sauvaget,Astrid Scharpantgen,Wolff Schmiegel,Carlo Senore,Maqsood Siddiqi,D. Sighoko,D. Sighoko,Richard D. Smith,Steve Smith,Stepan Suchanek,Eero Suonio,W. Tong,Sven Törnberg,E. Van Cutsem,Luca Vignatelli,P. Villain,Lydia Voti,Lydia Voti,Hidemi Watanabe,Joanna Watson,Sidney J. Winawer,G. Young,V. Zaksas,Marco Zappa,Roland Valori +113 more
TL;DR: An overview of the principles, recommendations and standards in the guidelines for quality assurance in CRC screening and diagnosis are presented in journal format in an open-access Supplement of Endoscopy.
Journal ArticleDOI
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies
Mireille J. M. Broeders,Sue Moss,Lennarth Nyström,Sisse Helle Njor,Håkan Jonsson,Ellen Paap,Nathalie J. Massat,Stephen W. Duffy,Elsebeth Lynge,Eugenio Paci +9 more
TL;DR: From a systematic literature review of European trend studies, the best ‘European’ estimate of breast cancer mortality reduction is 25–31% for women invited for screening, and 38–48% for Women actually screened.
Journal ArticleDOI
Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review
Donella Puliti,Stephen W. Duffy,Guido Miccinesi,Harry J. de Koning,Elsebeth Lynge,Marco Zappa,Eugenio Paci +6 more
TL;DR: The most plausible estimates of overdiagnosis range from 1% to 10%, and substantially higher estimates reported in the literature are due to the lack of adjustment for breast cancer risk and/or lead time.